tezepelumab sold brand name tezspire human monoclonal antibody used treatment tezepelumab blocks thymic stromal lymphopoietin epithelial cytokine suggested critical initiation persistence airway common side effects include arthralgia joint pain pharyngitis sore tezepelumab approved medical use united states december european union september us food drug administration fda considers firstinclass tezepelumab indicated addon maintenance treatment people aged twelve years older severe two main studies including adults adolescents inadequately controlled asthma showed tezepelumab effective reducing number severe asthma benefits side effects tezepelumab evaluated two clinical trials participants severe participants taking usual treatment addition participants received new treatment either tezepelumab neither participants investigators knew treatment benefit tezepelumab assessed measuring frequency asthma attacks exacerbations end week trials comparison fda approved tezepelumab based evidence two clinical trials navigator pathway participants severe safety efficacy tezepelumab evaluated two clinical trials participants severe trials conducted countries argentina australia austria bulgaria brazil canada czech republic france germany hungary israel japan lithuania latvia russia saudi arabia serbia slovakia south africa south korea taiwan ukraine united states july committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product tezspire intended addon treatment adults adolescents severe applicant medicinal product astrazeneca tezepelumab approved medical use european union september studied treatment chronic obstructive pulmonary disease chronic rhinosinusitis nasal polyps chronic spontaneous urticaria eosinophilic esophagitis phase iii trials tezepelumab demonstrated efficacy compared placebo patients severe uncontrolled structural studies xray crystallography showed tezepelumab competes critical part tslpr binding site immune activation dostarlimab ibalizumab httpsenwikipediaorgwikitezepelumab